The rationale for co-targeting the CDK4/6 and FGFR3 pathways in urothelial carcinoma
- Citation:
- Shohdy, K., R. Abdel-Malek, and B. Faltas,
"The rationale for co-targeting the CDK4/6 and FGFR3 pathways in urothelial carcinoma",
Expert Opinion on Therapeutic Targets, vol. 23, issue 2, pp. 83-86, 2019.
